两种二线方案治疗老年弥漫大B细胞淋巴瘤的临床观察  

Clinical observation on two kinds of second-line treatment regimens for elderly diffuse large B-cell lymphoma

作　　者：陈秀容[1] 蔡勇君[1] 杨瑜[1] 吴晖[1] 何鸿鸣[1] 陈道光[1] 陈英[1] 林剑扬[1] 陈宁斌[1] 郑艳彬[1] 邹思平[1] 王杰松[1] 王畅 Chen Xiurong;Cai Yongjun;Yang Yu;Wu Hui;He Hongming;Chen Daoguang;Chen Ying;Lin Jianyang;Chen Ningbin;Zheng Yanbin;Zou Siping;Wang Jiesong;Wang Chang(Department of Medical Oncology, Fujian Cancer Hospital, Affiliated Cancer Hospital of Fujian Medical University, Fuzhou 350014, China)

机构地区：[1]福建省肿瘤医院福建医科大学附属肿瘤医院肿瘤内科,福州350014

出　　处：《国际医药卫生导报》2019年第6期903-905,共3页International Medicine and Health Guidance News

摘　　要：目的探讨两种二线方案治疗老年弥漫大B细胞淋巴瘤(DLBCL)的临床效果。方法选取2010年7月至2018年7月本院收治的老年DLBCL患者96例为研究对象,回顾性分析患者临床资料,将采用R-ICE治疗的患者纳入对照组(n=48),采用R-GEMOX治疗的患者纳入观察组(n=48),对两组治疗效果进行对比分析。结果观察组治疗有效率97.92%略高于对照组93.75%,但差异无统计学意义(P>0.05);治疗后两组FOXP1、Livin表达阳性率均降低,且观察组FOXP1、Livin表达阳性率显著低于对照组(P<0.05);观察组不良反应发生率10.42%显著低于对照组27.08%(P<0.05)。结论R-GEMOX治疗DLBCL疗效略优于R-ICE方案,可显著降低FOXP1、Livin表达阳性率及不良反应发生率,值得在临床上推广应用。Objective To explore the clinical effect of two kinds of second-line treatment regimens for elderly diffuse large B-cell lymphoma (DLBCL). Methods A total of 96 elderly patients with DLBCL who were admitted to our hospital from July 2010 to July 2018 were selected as the subjects. The clinical data of the patients were retrospectively analyzed. Patients treated with R-ICE were included in control group (n=48), while those treated with R-GEMOX were included in observation group (n=48). The treatment effects were compared between the two groups. Results The response rate of the observation group was slightly higher than that of the control group (97.92% vs.93.75%)(P>0.05). The positive expression rates of FOXP1 and Livin in both groups decreased after treatment, and the positive expression rates of FOXP1 and Livin in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (10.42% vs.27.08%)(P<0.05). Conclusion The curative effect of R-GEMOX is better than R-ICE in the treatment of DLBCL. The former can significantly reduce the positive expression rates of FOXP1 and Livin and the incidence of adverse reactions.

关 键 词：R-ICE R-GEMOX 老年 弥漫大B 细胞淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]